Search results
Results from the WOW.Com Content Network
Individuals with a fatty-acid metabolism disorder are unable to metabolize this fat source for energy, halting bodily processes. [1] Most individuals with a fatty-acid metabolism disorder are able to live a normal active life with simple adjustments to diet and medications. If left undiagnosed many complications can arise.
Lipodystrophy syndromes are a group of genetic or acquired disorders in which the body is unable to produce and maintain healthy fat tissue. [ 1 ] [ 2 ] The medical condition is characterized by abnormal or degenerative conditions of the body's adipose tissue .
Bimagrumab, an experimental drug, works by inhibiting the action of myostatin, which limits the size of skeletal muscle. The drug has shown the ability to increase lean mass simultaneously to decreasing fat mass in obese humans, which is beneficial because it preserves or increases energy expenditure while reducing risks associated with excess fat.
Hormonal disorder due to the body's inability to properly metabolize fat; Increase in fat cells ; Enzymatic defect or a change in the surface of the cells that could prevent the breakdown of fat; Poor lymphatic drainage; Defective regulation of mitochondria in brown fat. Brown fat is responsible for causing heat in times of stress or cold.
When a drug is on the FDA’s shortage list, compounded versions of it become legal. Since 2022, there’s been a shortage of Mounjaro and Zepbound due to the increase in demand for the drugs ...
The gut microbiota, which is a population of microbes that live in the human digestive system, also has an important part in metabolism and generally has a positive function for its host. In terms of pathophysiological/mechanism interactions, an abnormal gut microbiota can play a role in metabolic disorder related obesity. [8]
Studies examining the efficacy of GLP-1 drugs used for weight loss have generally quantified changes in fat and lean mass, with changes in lean mass serving as a surrogate for muscle mass.
Levothyroxine, a drug used to treat hypothyroidism, can lead to reduced bone mass and density in older adults with normal thyroid levels, a small cohort study has shown.